China’s pharmaceutical innovation stands at a pivotal inflection point. After a decade of explosive growth, the industry is navigating a period of “capital winter,” intense policy-driven competition, and a strategic shift from the pursuit of quantity to the mandate of quality. However, this pressure is also a catalyst, forcing a clear-eyed re-evaluation of the path forward. Today, China is not just a vast clinical trial hub or a manufacturing powerhouse; it is defining its ambition to become a “world new drug creation center” by 2035.
- The “Innovation Pivot”: From Fast-Follower to First-in-Class
- The “Globalization 2.0” Playbook: From BD Transactions to Enduring Value
- The “Dual Engine” of Policy: Regulatory Acceleration Meets Payment Reformation
- Convergence and Concentration: Surviving the “Great Integration”
- The Ultimate Alignment: Bridging the Pipeline to Unmet Clinical Need
中国医药创新正站在一个关键的历史转折点。经历十年高速发展之后，行业步入“资本寒冬”，政策驱动的同质化竞争日趋激烈，发展逻辑正从追求数量向锚定质量深刻转型。然而，压力亦是催化剂，正倒逼全行业以更清醒的姿态重新审视前路。今天，中国不再仅仅是全球临床试验的聚集地或制药生产基地，它正在以2035年建成“世界级新药创制中心”为愿景，重新定义自己的全球坐标。
- 创新力的转向：从快速跟跑到全球首创
- 全球化0剧本：从授权交易到持久价值
- 政策双引擎：监管提速与支付改革的同频共振
- 收敛与集中：如何在“大整合期”存活并胜出
- 终极对齐：让管线与未满足的临床需求精准接驳